A Cambridge-developed vaccine candidate against SARS-CoV-2 could begin clinical trials in the UK in late autumn or early next year, thanks to a £1.9million award from the UK government.
Innovate UK, the UK government’s innovation agency, has provided the funding for a collaboration between Cambridge spin-out company DIOSynVax (which is contributing an additional £400,000 to the trial), the University of Cambridge and the University Hospital Southampton NHS Foundation Trust.